Sepsis & infection

Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial

Am J Respir Crit Care MedPublished Randomised controlled trial

Primary result · Change in SOFA scoreResult — go to the resultMedian difference 1 95% CI 0–3

Authors' conclusion

Among patients with septic shock and persistent hypoperfusion, iloprost did not reduce the severity of organ failure.

Study context

Population
Adults with septic shock and persistent hypoperfusion (increased capillary refill time and/or skin mottling)236 analysed
Participants
240 adults
Comparison
48-h IV iloprost infusion vs placebo
Primary endpoint
Change in Sequential Organ Failure Assessment (SOFA) score from randomisation to Day 7
Follow-up
Day 7
Methodological detailsmulticentre, double-blind, placebo-controlled
  • Multicentre
  • Double-blind
  • Placebo-controlled

Primary result

Change in SOFA score

Median difference

1

95% CI 0–3

P = 0.12

Change by group

Iloprost

−4

median · IQR −7–7

Placebo

−5

median · IQR −8–5

Iloprost vs Placebo
median difference 1 (95% CI 0–3); P = 0.12

As reported in the abstract

Secondary outcomes

OutcomeIloprostPlaceboRR (95% CI)
Mortality · 28 days42%39%1.08 (0.80–1.5)

Median

OutcomeIloprostPlaceboMedian difference (95% CI)
Mean daily (average) SOFA score11.2 (IQR 7.4–15.9)10.5 (IQR 6.8–16.5)0.25 (−1.1 to 1.8)
OutcomeMedian difference (days) (95% CI)
Ventilation-free survival days · 28 days0 (0–0)
Vasopressor-free survival days · 28 days0 (−1 to 1)
RRT-free survival days · 28 days0 (0–0)

Safety

Severe adverse events

P = 0.06

Original publication

Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial. Am J Respir Crit Care Med. Published 1 July 2025. doi:10.1164/rccm.202410-1924oc

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.